

Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

NCT06629818

Status	RECRUITING
Phase	Phase 2
Sponsor	Peking Union Medical College Hospital
Enrollment	36 participants

Key Eligibility Criteria

Inclusion (3)

- Biopsy proved treatment-naïve AL amyloidosis
- Fluorescence in situ hybridization (FISH) t(11;14) e 10%
- dFLC \geq 50mg/L

Exclusion (11)

- Co-morbidity of uncontrolled infection
- Co-morbidity of other active malignancy
- Co-diagnosis of multiple myeloma or waldenstrom macroglobulinemia
- Co-morbidity of grade 2 Mobitz II or grade 3 atrioventricular block (except for those with implanted pacemaker)
- Co-morbidity of sustained or recurrent nonsustained ventricular tachycardia
- ... and 6 more (see full listing online)

Locations (1 total)

Peking Union Medical College Hospital, Beijing, Beijing Municipality, China